Bharat Biotech collaborates with Bilthoven Biologicals to strengthen global polio eradication

India’s Bharat Biotech (BBIL) and Bilthoven Biologicals (BBio), the Dutch subsidiary of the Serum Institute of India, have inked a pact to manufacture oral polio vaccines (OPVs) in India. Under an agreement, the vaccines will be produced in India utilizing drug substances supplied by the Dutch company.

Both entities will collaborate to secure the necessary regulatory approvals and licenses essential for the commercial production of OPVs in India. The manufactured vaccines will cater to both domestic and international markets.

Adar Poonawalla, chief executive of Serum Institute of India, emphasized the companies' shared vision of eradicating polio worldwide. This is a "crucial step towards reducing the impact of this deadly disease on vulnerable populations," he said.